Treatment of chlamydial infections

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 545-552

  Hammerschlag, Margaret R ^a   Kohlhoff, Stephan A ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Chlamydia pneumoniae; Chlamydia trachomatis; Chlamydiae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; GENTAMICIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLONE; RIFAMPICIN; SOLITHROMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ASTHMA; BACTERIAL STRAIN; BACTERIUM DETECTION; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL PNEUMONIA; CHLAMYDIAL URETHRITIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; DELIVERY; DIAGNOSTIC TEST; DNA SYNTHESIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FIRST TRIMESTER PREGNANCY; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LIFE CYCLE; LYMPHOGRANULOMA VENEREUM; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; NUCLEIC ACID AMPLIFICATION; PATIENT COMPLIANCE; PELVIC INFLAMMATORY DISEASE; PREGNANT WOMAN; PROTEIN SYNTHESIS; RESPIRATORY TRACT INFECTION; REVIEW; SERODIAGNOSIS; SEXUAL TRANSMISSION; SINGLE DRUG DOSE; TREATMENT DURATION;

ANIMALS; ANTI-INFECTIVE AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDIAL PNEUMONIA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857339800     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.658776     Document Type: Review

References (60)

1. Centers for Disease Control and Prevention. 2010 Sexually transmitted diseases treatment guidelines. MMWR 2010;59(RR-12):1-110
2. Hammerschlag MR, Kohlhoff SA, Darville T. Chlamydia pneumoniae and Chlamydia trachomatis. In: Fratamico PM, Smith JL, Brogden KA, editors. Sequelae and long-term consequences of infectious diseases. American Society for Microbiology; Washington, DC: 2009. p. 27-52
3. Rockey DD, Lenart J, Stephens RS. Genome sequencing and our understanding of chlamydiae. Infect Immun 2000;68:5473-9
4. Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, et al. Persistence of chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000;44:3288-97 (Pubitemid 33009485)
5. Eickhoff M, Thalmann J, Hess S, et al. Host cell responses to chlamydia pneumoniae in gamma interferon-induced persistence overlap those of productive infection and are linked to genes involved in apoptosis, cell cycle, and metabolism. Infect Immun 2007;75:2853-63 (Pubitemid 46870166)
6. Harper A, Pogson CI, Jones ML, et al. Chlamydial development is adversely affected by minor changes in amino acid supply, blood plasma amino acids levels, and glucose deprivation. Infect Immun 2000;68:1457-64 (Pubitemid 30108544)
7. Hogan RJ, Mathews SA, Mukhopadhyay S, et al. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun 2004;72:1843-55 (Pubitemid 38419894)
8. Mpiga P, Ravaoarinoro M. Chlamydia trachomatis persistence: an update. Microbiol Res 2006;161:9-19 (Pubitemid 41773108)
9. Mukhopadhyay S, Miller RD, Sullivan ED, et al. Protein expression profiles of Chlamydia pneumoniae in models of persistence versus those of heat shock stress response. Infect Immun 2006;74:3853-63 (Pubitemid 43993316)
10. Polkinghorne A, Hogan RJ, Vaughn L, et al. Differential expression of chlamydial signal transduction genes in normal and interferon gamma-induced persistent Chlamydophila pneumoniae infections. Microbes Infect 2006;8:61-72 (Pubitemid 43139293)
11. Hogan R, Mathews S, Kutlin A, et al. Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infections. Microbes Pathog 2003;34:11-16 (Pubitemid 36287210)
12. Kutlin A, Roblin PM, Hammerschlag MR. Effect of prolonged treatment with azithromycin, clarithromycin and levofloxacin on Chlamydia pneumoniae in a continuous infection model. Antimicrob Agents Chemother 2002;46:409-12 (Pubitemid 34087188)
13. Senn L, Hammerschlag MR, Greub G. Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother 2005;6:1-10
14. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2002;47:636-42 (Pubitemid 36158094)
15. Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol 2010;5:1427-42
16. Ghuysen JM, Goffin C. Lack of cell wall peptidoglycan versus penicillin sensitivity: new insights into the chlamydial anomaly. Antimicrob Agents Chemother 1999;43:2339-44 (Pubitemid 29471206)
17. Stamm WE. Chlamydia trachomatis infections in the adult. In: Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Cory L, Cohen M, Watts H, editors. Sexually Transmitted Diseases. 4th edition. McGraw Hill; New York: 2008. p. 575-94
18. Dessus-Babus S, Bebear CM, Charron A, et al. Sequencing of gyrase and topoisomerase IV quinolones sequence-determining regions of Chlamydia trachomatis and characterization of quinolones resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998;42:2474-81 (Pubitemid 28462882)
19. Morrissey I, Salman H, Bakker S, et al. Serial passage of Chlamydia spp. in subinhibitory fluoroquinolone concentrations. J Antimicrob Chemother 2002;49:757-61 (Pubitemid 34537635)
20. Kutlin A, Kohlhoff S, Roblin P, et al. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis. Antimicrob Agents Chemother 2005;49:903-7 (Pubitemid 40327703)
21. Jones RB, Van Der Pol B, Martin DH, et al. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990;162:1309-15
22. Somani J, Bhullar VB, Workowski KA, et al. Multiple drug- resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000;181:1421-7 (Pubitemid 30252548)
23. Misyurina OY, Chipitsyna EV, Finashutina YP, et al. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob Agents Chemother 2004;48:1347-9 (Pubitemid 38405492)
24. Bhengraj AR, Vardhan H, Srivastava P, et al. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy 2010;56:371-7
25. Bhengraj AR, Srivastava P, Mittal A. Lack of mutation in macrolide resistance genes in Chlamydia trachomatis clinical isolates with decreased susceptibility to azithromycin. Int J Antimicrob Agents 2011;38:178-9
26. Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in community acquired pneumonia in children: comparative safety and efficacy of clarithromycin and erythromycin suspensions. Pediatr Infect Dis J 1995;14:471-7
27. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrob Agents Chemother 1998;42:194-6 (Pubitemid 28053353)
28. Harris J-A, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J 1998;17:865-71 (Pubitemid 28506406)
29. Hammerschlag MR, Roblin PM. Microbiologic efficacy of levofloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Antimicrob Agents Chemother 2000;44:1409 (Pubitemid 30228336)
30. Hammerschlag MR, Roblin PM. Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. Int J Antimicrob Agents 2000;15:149-52 (Pubitemid 30347257)
31. Roblin PM, Montalban G, Hammerschlag MR. Susceptibility to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994;38:1588-9 (Pubitemid 24203573)
32. Riska PF, Kutlin A, Ajiboye P, et al. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. Antimicrob Agents Chemother 2004;48:3586-690
33. Rupp J, Gebert A, Solbach W, et al. Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae. Antimicrob Agents Chemother 2005;49:406-7 (Pubitemid 40065818)
34. Kutlin A, Roblin PM, Hammerschlag MR. Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother 2002;49:763-7 (Pubitemid 34537636)
35. Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010;201:42-51
36. Wang SA, Papp JR, Stamm WE, et al. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis 2005;191:917-23 (Pubitemid 40349807)
37. Rice RJ, Bhullar V, Mitchell SH, et al. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995;39:760-2
38. Samra Z, Rosenberg S, Soffer Y, et al. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 2001;39:177-9 (Pubitemid 32406174)
39. Hong KC, Schachter J, Moncada J, et al. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis 2009;15:1088-90
40. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis 2007;44:568-76 (Pubitemid 46233262)
41. Lau C-Y, Qureshi AK. Azithromycin versus doxycycline for genital Chlamydia infections. A meta-analysis of randomized clinical trials. Sex Transm Dis 2002;29:497-502 (Pubitemid 35001337)
42. Judlin P, Liao Q, Liu Z, et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010;117:1475-84
43. Gaydos CA, Crotchfelt KA, Howell MR, et al. Molecular amplification assays to detect chlamydial infections in urine specimens from high school female students ant to monitor the persistence of chlamydial DNA after therapy. J Infect Dis 1998;177:417-24 (Pubitemid 28063768)
44. Renault CA, Israelski DM, Levy V, et al. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health 2011;8:69-73
45. Pitsouni E, Iavazzo C, Athtanasiou S, et al. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2007;30:213-21 (Pubitemid 47126817)
46. de Vries HJC, Smelov V, Middleburg JG, et al. Delayed microbial cure of lymphogranuloma venereum proctitis with doxycycline treatment. Clin Infect Dis 2009;48:e53-6
47. Mechai F, de Barbeyrac D, Aoun O, et al. Doxycycline failure in lymphogranuloma venereum. Sex Transm Infect 2010;86:278-9
48. Nieuwenhuis RF, Ossewaarde JM, van der Meijden WI, et al. Unusual presentation of early lymphogranuloma venereum in an HIV-1 infected patient: effective treatment with 1 g azithromycin. Sex Transm Infect 2003;79:453-5 (Pubitemid 38021403)
49. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-71
50. Vergis EN, Indorf A, File TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch Intern Med 2000;160:1294-300 (Pubitemid 30252775)
51. Pletz MW, Rohde G, Schutte H, et al. Epidemiology and aetiology of community-acquired pneumonia. Dtsch Med Wochenschr 2011;136:775-80
52. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics against atypical pathogens in nonsevere community-acquired pneumonia: meta-analysis. BMJ 2005;330:456
53. Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999;18:98-104 (Pubitemid 29101880)
54. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010;126:747-53
55. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006;354:1589-600
56. Roblin PM, Kohlhoff SA, Parker C, et al. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother 2010;54:1358-9
57. Jones RN, Biedenbach DJ, Roblin PM, et al. Update on fusidic acid (CEM-102) tested against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrob Agents Chemother 2010;54:4518-19
58. Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400 (Pubitemid 351578190)
59. Stamm WE, Batteiger BE, McCormack WM, et al. A randomized double-blind study comparing single-dose rifalazil with single dose azithromycin for empirical treatment of nongonococal urethritis in men. Sex Transm Dis 2007;34:545-52 (Pubitemid 47207142)
60. Hammerschlag MR, Kohlhoff SA, Apfalter P. Chlamydophila (Chlamydia) pneumoniae. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th edition. Elsevier, Inc.; Philadephia, PA: 2009. p. 2467-75